临床实践指南:成人颈部肿块的评估
该指南针对≥18岁颈部肿块患者,目标读者包括急诊科等首诊医生。指南提出:无感染病史且肿块持续≥2周无显著波动或持续时间不确定,或体检有固定于邻近组织、质硬、>1.5 cm、表面皮肤溃疡中≥1项,为恶性风险增高。对风险增高者,强推荐增强颈部CT(或MRI),推荐针对性体检(含喉、舌根、咽黏膜)、细针穿刺而非开放活检、囊性肿块持续评估至确诊、FNA与影像无诊断时加做辅助检查、开放活检前全麻下评估上呼吸消化道;不推荐常规抗生素除非有细菌感染征象。
要点
- 成人颈部肿块应视为恶性直到被证明为其他性质;无感染病史且持续≥2周无显著波动或持续时间不确定即为恶性风险增高。
- 体检固定于邻近组织、质硬、>1.5 cm或表面皮肤溃疡中≥1项,也判定为恶性风险增高。
- 对恶性风险增高者,强推荐增强颈部CT(或MRI);应行针对性体检包括喉、舌根、咽黏膜可视化。
- 诊断未明时行细针穿刺而非开放活检;囊性肿块不应假定良性,应持续评估至确诊。
- 不推荐常规抗生素,除非有细菌感染症状和体征;FNA和影像无诊断时加做辅助检查,开放活检前全麻下评估上呼吸消化道。
适用人群与场景
- 目标患者为任何≥18岁有颈部肿块者;本指南不适用于儿童。
- 目标临床医生为颈部肿块患者可能首先遇到的任何临床医生,包括初级保健、牙科和急诊医学临床医生,以及参与诊断颈部肿块的病理科和放射科医生。
- 本指南仅涉及成人颈部肿块可能恶性的适当检查以加快诊断和转诊至头颈癌专科医生,不涉及已知源于甲状腺、唾液腺、下颌或牙科病变的颈部肿块的管理,也不涉及特定病理实体的后续管理。
诊断标准与关键阈值
- 恶性风险增高:患者缺乏感染性病因史,且肿块已存在≥2周无显著波动,或肿块持续时间不确定。
- 恶性风险增高:基于≥1项体检特征:固定于邻近组织、质硬、大小>1.5 cm或表面皮肤溃疡。
- 初始病史和体检用于识别其他提示恶性风险增高的可疑发现。
- 对恶性风险不增高者,应告知患者触发额外评估的标准,并记录随访计划以评估消退或最终诊断。
处置流程与药物剂量
- 对恶性风险增高者,临床医生应开具增强颈部计算机断层扫描(或磁共振成像)(强推荐)。
- 对恶性风险增高者,应进行或转诊进行针对性体检,包括喉、舌根和咽黏膜的可视化。
- 对恶性风险增高且诊断仍不明确者,应行细针穿刺而非开放活检,或转诊至能行FNA者。
- 对经FNA或影像学确定为囊性颈部肿块且恶性风险增高者,应继续评估直至获得诊断,不应假定肿块为良性。
- 对恶性风险增高且FNA和影像后仍无诊断者,应根据病史和体检获取额外辅助检查。
- 对恶性风险增高且FNA、影像和/或辅助检查后无诊断或未确定原发部位者,应在开放活检前推荐全麻下评估上呼吸消化道。
- 不推荐常规处方抗生素治疗颈部肿块患者,除非有细菌感染的症状和体征。
- 对恶性风险增高者,临床医生或其指定人员应向患者解释风险增高的意义并解释任何推荐的诊断检查。
红旗征与不能漏的情况
- 无感染病史且肿块持续≥2周无显著波动或持续时间不确定,提示恶性风险增高。
- 肿块固定于邻近组织、质硬、>1.5 cm或表面皮肤溃疡,提示恶性风险增高。
- 囊性颈部肿块经FNA或影像学确定后,不应假定为良性,应继续评估至确诊。
研究设计与关键结果
- 该指南由指南制定组制定,针对成人颈部肿块评估提出可操作声明;制定组做出1条强推荐和若干条推荐,并推荐不常规使用抗生素除非有细菌感染征象。
- 指南指出成人持续性颈部肿块大多为肿瘤,恶性肿瘤远超其他病因;无症状颈部肿块可能是头颈癌(如鳞状细胞癌、淋巴瘤、甲状腺或唾液腺癌)的初始或唯一临床表现。
- 指南指出尽管检测手段有显著进步,诊断延迟仍常见;目前仅有1部循证临床实践指南协助临床医生评估成人颈部肿块。
证据类型、等级与局限
- 证据类型:临床实践指南(指南/共识)。
- 指南制定组在可能处纳入证据以促进高质量和成本效益的医疗。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急诊等首诊场景中,对成人颈部肿块应首先按恶性风险分层:无感染病史且持续≥2周无显著波动或持续时间不确定者,视为恶性风险增高。
- 对恶性风险增高者,强推荐增强颈部CT(或MRI),并行针对性体检(含喉、舌根、咽黏膜可视化),避免延误诊断。
- 诊断未明时用细针穿刺而非开放活检;囊性肿块不应假定良性,应持续评估至确诊。
- 不常规处方抗生素除非有细菌感染症状和体征;对风险增高者应解释风险意义并记录随访计划。
指南或共识出处
- Clinical Practice Guideline: Evaluation of the Neck Mass in Adults(Otolaryngol Head Neck Surg)
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Objective Neck masses are common in adults, but often the underlying etiology is not easily identifiable. While infections cause most of the neck masses in children, most persistent neck masses in adults are neoplasms. Malignant neoplasms far exceed any other etiology of adult neck mass. Importantly, an asymptomatic neck mass may be the initial or only clinically apparent manifestation of head and neck cancer, such as squamous cell carcinoma (HNSCC), lymphoma, thyroid, or salivary gland cancer. Evidence suggests that a neck mass in the adult patient should be considered malignant until proven otherwise. Timely diagnosis of a neck mass due to metastatic HNSCC is paramount because delayed diagnosis directly affects tumor stage and worsens prognosis. Unfortunately, despite substantial advances in testing modalities over the last few decades, diagnostic delays are common. Currently, there is only 1 evidence-based clinical practice guideline to assist clinicians in evaluating an adult with a neck mass. Additionally, much of the available information is fragmented, disorganized, or focused on specific etiologies. In addition, although there is literature related to the diagnostic accuracy of individual tests, there is little guidance about rational sequencing of tests in the course of clinical care. This guideline strives to bring a coherent, evidence-based, multidisciplinary perspective to the evaluation of the neck mass with the intention to facilitate prompt diagnosis and enhance patient outcomes. Purpose The primary purpose of this guideline is to promote the efficient, effective, and accurate diagnostic workup of neck masses to ensure that adults with potentially malignant disease receive prompt diagnosis and intervention to optimize outcomes. Specific goals include reducing delays in diagnosis of HNSCC; promoting appropriate testing, including imaging, pathologic evaluation, and empiric medical therapies; reducing inappropriate testing; and promoting appropriate physical examination when cancer is suspected. The target patient for this guideline is anyone ≥18 years old with a neck mass. The target clinician for this guideline is anyone who may be the first clinician whom a patient with a neck mass encounters. This includes clinicians in primary care, dentistry, and emergency medicine, as well as pathologists and radiologists who have a role in diagnosing neck masses. This guideline does not apply to children. This guideline addresses the initial broad differential diagnosis of a neck mass in an adult. However, the intention is only to assist the clinician with a basic understanding of the broad array of possible entities. The intention is not to direct management of a neck mass known to originate from thyroid, salivary gland, mandibular, or dental pathology as management recommendations for these etiologies already exist. This guideline also does not address the subsequent management of specific pathologic entities, as treatment recommendations for benign and malignant neck masses can be found elsewhere. Instead, this guideline is restricted to addressing the appropriate work-up of an adult patient with a neck mass that may be malignant in order to expedite diagnosis and referral to a head and neck cancer specialist. The Guideline Development Group sought to craft a set of actionable statements relevant to diagnostic decisions made by a clinician in the workup of an adult patient with a neck mass. Furthermore, where possible, the Guideline Development Group incorporated evidence to promote high-quality and cost-effective care. Action Statements The development group made a strong recommendation that clinicians should order a neck computed tomography (or magnetic resonance imaging) with contrast for patients with a neck mass deemed at increased risk for malignancy. The development group made the following recommendations: (1) Clinicians should identify patients with a neck mass who are at increased risk for malignancy because the patient lacks a history of infectious etiology and the mass has been present for ≥2 weeks without significant fluctuation or the mass is of uncertain duration. (2) Clinicians should identify patients with a neck mass who are at increased risk for malignancy based on ≥1 of these physical examination characteristics: fixation to adjacent tissues, firm consistency, size >1.5 cm, or ulceration of overlying skin. (3) Clinicians should conduct an initial history and physical examination for patients with a neck mass to identify those with other suspicious findings that represent an increased risk for malignancy. (4) For patients with a neck mass who are not at increased risk for malignancy, clinicians or their designees should advise patients of criteria that would trigger the need for additional evaluation. Clinicians or their designees should also document a plan for follow-up to assess resolution or final diagnosis. (5) For patients with a neck mass who are deemed at increased risk for malignancy, clinicians or their designees should explain to the patient the significance of being at increased risk and explain any recommended diagnostic tests. (6) Clinicians should perform, or refer the patient to a clinician who can perform, a targeted physical examination (including visualizing the mucosa of the larynx, base of tongue, and pharynx) for patients with a neck mass deemed at increased risk for malignancy. (7) Clinicians should perform fine-needle aspiration (FNA) instead of open biopsy, or refer the patient to someone who can perform FNA, for patients with a neck mass deemed at increased risk for malignancy when the diagnosis of the neck mass remains uncertain. (8) For patients with a neck mass deemed at increased risk for malignancy, clinicians should continue evaluation of patients with a cystic neck mass, as determined by FNA or imaging studies, until a diagnosis is obtained and should not assume that the mass is benign. (9) Clinicians should obtain additional ancillary tests based on the patient's history and physical examination when a patient with a neck mass is deemed at increased risk for malignancy who does not have a diagnosis after FNA and imaging. (10) Clinicians should recommend evaluation of the upper aerodigestive tract under anesthesia, before open biopsy, for patients with a neck mass deemed at increased risk for malignancy and without a diagnosis or primary site identified with FNA, imaging, and/or ancillary tests. The development group recommended against clinicians routinely prescribing antibiotic therapy for patients with a neck mass unless there are signs and symptoms of bacterial infection.
参考来源
- Pynnonen MA, Gillespie MB, Roman B, et al. Clinical Practice Guideline: Evaluation of the Neck Mass in Adults. Otolaryngol Head Neck Surg. 2017. PMID: 28891406. doi:10.1177/0194599817722550
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。